Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:43:18.331Z.
Calculation as of: 2026-10-06T20:43:18.331Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1553418876f95fd726688d6af936ce5a4046000e23636182a7ec29874c901e9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Telomir Pharmaceuticals, Inc. Common Stock
Market Cap
$82.53M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.47M
PS Ratio
162.34
TTM Avg
221.52
3Y Avg
228.25
5Y Avg
248.51
Market Cap
$82.59M
PS Ratio
N/A
TTM Avg
11653.16
3Y Avg
16737.74
5Y Avg
42439.00
Market Cap
$79.61M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $82.53M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | 162.34 | 221.52 | 228.25 | 248.51 |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | N/A | 11653.16 | 16737.74 | 42439.00 |
| LENSAR Inc (LNSR)vs › | $82.29M | 1.37 | 2.06 | 1.84 | 1.67 |
| MediciNova, Inc. (MNOV)vs › | $81.22M | 88.23 | 216.46 | 165.81 | 579.35 |
| Nutriband Inc. (NTRB)vs › | $81.20M | 50.20 | 25.94 | 25.30 | 23.23 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | 37.86 | 49.38 | 546.61 | 880.05 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-17 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
